SIC
ARQT icon

SJS Investment Consulting’s Arcutis Biotherapeutics ARQT Stock Holding History

SJS Investment Consulting’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.83K Sell
108
-53
-33% -$1.24K ﹤0.01% 1629
2026
Q1 		$3.79K Sell
161
-368
-70% -$9.39K ﹤0.01% 1117
2025
Q4 		$15.4K Buy
529
+391
+283% +$10K ﹤0.01% 692
2025
Q3 		$2.6K Hold
138
– – ﹤0.01% 778
2025
Q2 		$1.94K Buy
+138
New +$1.94K ﹤0.01% 584
2024
Q4 		– Sell
-185
Closed -$1.72K – 1614
2024
Q3 		$1.72K Buy
+185
New +$1.83K ﹤0.01% 862

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SJS Investment Consulting's ARQT Position: Q2 2026 in Review

SJS Investment Consulting reduced its Arcutis Biotherapeutics (ARQT) stake by 33% in Q2 2026, selling an estimated $1.24K and leaving 108 shares worth $2.83K. The position accounts for ﹤0.01% of the portfolio, ranked #1629.

SJS Investment Consulting first reported a position in ARQT in Q3 2024 and has held it in 6 quarters since. The position peaked at $15.4K in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • SJS Investment Consulting held 108 shares of Arcutis Biotherapeutics worth $2.83K as of Q2 2026.
  • SJS Investment Consulting sold 53 Arcutis Biotherapeutics shares in Q2 2026, an estimated $1.24K.
  • Arcutis Biotherapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #1629 holding.
  • SJS Investment Consulting first reported a position in Arcutis Biotherapeutics in Q3 2024 and has held it in 6 quarters since.
  • SJS Investment Consulting's Arcutis Biotherapeutics position peaked at $15.4K in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.